Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations
Article first published online: 18 NOV 2005
American Journal of Reproductive Immunology
Volume 54, Issue 6, pages 352–357, December 2005
How to Cite
Feinberg, B. B., Jack, R. M., Mok, S. C. and Anderson, D. J. (2005), Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations. American Journal of Reproductive Immunology, 54: 352–357. doi: 10.1111/j.1600-0897.2005.00318.x
- Issue published online: 18 NOV 2005
- Article first published online: 18 NOV 2005
- Submitted May 16, 2005; revised July 12, 2005; accepted July 13, 2005.
- immune complex;
Erythrocyte complement receptor type 1 (E-CR1) is the main immune complex clearance mechanism in humans. Decreased E-CR1 expression is noted in certain inflammatory disorders. Recent evidence implicates inflammation in the pathogenesis of preeclampsia. We investigated whether E-CR1 is decreased in preeclampsia.
Method of study
E-CR1 protein expression was quantified by radioimmunoassay. Plasma concentration of soluble CR1 was quantified using a specific enzyme linked immunosorbent assay. Quantitative genotypes were evaluated by HindIII restriction fragment length polymorphism analysis.
E-CR1 expression was reduced in patients with preeclampsia. Lack of neoantigen expression (indicative of enzymatic cleavage of CR1) or elevated plasma-soluble CR1 was evidence against an acquired loss of E-CR1. Genotype analysis revealed a higher frequency of a CR1 allele associated with low E-CR1 expression in preeclampsia when compared with normal pregnant controls.
E-CR1 expression is decreased in preeclamptic patients and levels correlate with severity of disease. This condition may have a genetic basis in some patients.